Free Trial
NASDAQ:XOMA

XOMA (XOMA) Stock Price, News & Analysis

$27.00
+0.82 (+3.13%)
(As of 07/12/2024 ET)
Today's Range
$26.03
$27.00
50-Day Range
$22.31
$27.00
52-Week Range
$13.48
$27.36
Volume
14,540 shs
Average Volume
29,533 shs
Market Capitalization
$314.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.00

XOMA MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
111.1% Upside
$57.00 Price Target
Short Interest
Bearish
2.08% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.22
Upright™ Environmental Score
News Sentiment
0.62mentions of XOMA in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.76) to ($1.20) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.71 out of 5 stars

Medical Sector

242nd out of 915 stocks

Pharmaceutical Preparations Industry

105th out of 433 stocks

XOMA stock logo

About XOMA Stock (NASDAQ:XOMA)

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

XOMA Stock Price History

XOMA Stock News Headlines

XOMA (NASDAQ:XOMA) Stock Rating Reaffirmed by HC Wainwright
Anyone can do this, rich and poor alike
I’ve been a financial analyst for almost three decades, but I don’t think I’ve ever seen anything quite like this before.
XOMA Declares Quarterly Preferred Stock Dividends
3 Crazy Good Stocks to Buy With $500 Right Now
Anyone can do this, rich and poor alike
I’ve been a financial analyst for almost three decades, but I don’t think I’ve ever seen anything quite like this before.
Cracking The Code: Understanding Analyst Reviews For XOMA
Actym Therapeutics Appoints Thomas Smart as CEO
XOMA Corporation Announces Closing of Tender Offer
See More Headlines
Receive XOMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
7/13/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:XOMA
CUSIP
98419J10
Employees
13
Year Founded
1981

Price Target and Rating

Average Stock Price Target
$57.00
High Stock Price Target
$74.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+111.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-40,830,000.00
Net Margins
-705.23%
Pretax Margin
-681.69%

Debt

Sales & Book Value

Annual Sales
$4.76 million
Book Value
$7.72 per share

Miscellaneous

Free Float
10,801,000
Market Cap
$314.28 million
Optionable
Optionable
Beta
0.93

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

XOMA Stock Analysis - Frequently Asked Questions

How have XOMA shares performed this year?

XOMA's stock was trading at $18.50 at the beginning of 2024. Since then, XOMA shares have increased by 45.9% and is now trading at $27.00.
View the best growth stocks for 2024 here
.

How were XOMA's earnings last quarter?

XOMA Co. (NASDAQ:XOMA) issued its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by $0.15. The biotechnology company earned $1.49 million during the quarter, compared to the consensus estimate of $0.96 million. XOMA had a negative net margin of 705.23% and a negative trailing twelve-month return on equity of 26.00%.

What is John Varian's approval rating as XOMA's CEO?

11 employees have rated XOMA Chief Executive Officer John Varian on Glassdoor.com. John Varian has an approval rating of 73% among the company's employees.

How do I buy shares of XOMA?

Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of XOMA own?

Based on aggregate information from My MarketBeat watchlists, some other companies that XOMA investors own include Cytokinetics (CYTK), Alnylam Pharmaceuticals (ALNY), Ascent Solar Technologies (ASTI), CTI BioPharma (CTIC), OPKO Health (OPK) and Uranium Energy (UEC).

This page (NASDAQ:XOMA) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners